REGENXBIO Inc. (NASDAQ:RGNX) CEO Kenneth T. Mills Sells 1,500 Shares
REGENXBIO Inc. (NASDAQ:RGNX) CEO Kenneth T. Mills sold 1,500 shares of the firm’s stock in a transaction dated Thursday, January 7th. The shares were sold at an average price of $50.01, for a total value of $75,015.00. Following the completion of the transaction, the chief executive officer now owns 283,484 shares of the company’s stock, valued at approximately $14,177,034.84. The sale was disclosed in a document filed with the SEC, which is available through this link.
REGENXBIO stock opened at $47.43 on Thursday. REGENXBIO Inc. has a twelve month low of $20.03 and a twelve month high of $54.97. The stock has a market cap of $1.77 billion, a P/E ratio of -12.99 and a beta of 0.95. The company’s 50-day moving average price is $43.11 and its two-hundred day moving average price is $34.72.
REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $1.12. The company had revenue of $98.91 million for the quarter, compared to analyst estimates of $24.80 million. REGENXBIO had a negative return on equity of 31.06% and a negative net margin of 222.24%. The firm’s quarterly revenue was up 572.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.94) earnings per share. As a group, equities analysts forecast that REGENXBIO Inc. will post -2.97 EPS for the current year.
RGNX has been the subject of several recent research reports. TheStreet raised REGENXBIO from a “d+” rating to a “c” rating in a research report on Monday. Zacks Investment Research downgraded REGENXBIO from a “hold” rating to a “sell” rating in a report on Tuesday, January 5th. SVB Leerink lifted their price objective on shares of REGENXBIO from $34.00 to $37.00 and gave the company a “market perform” rating in a research report on Wednesday, January 6th. Raymond James upgraded REGENXBIO from an “outperform” rating to a “strong-buy” rating and set a $60.00 price objective on the stock in a research note on Wednesday, January 6th. Finally, BidaskClub upgraded REGENXBIO from a “buy” rating to a “strong-buy” rating in a research note on Friday, December 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. REGENXBIO has a consensus rating of “Buy” and an average target price of $57.00.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Featured Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.